Categories: News

Rénibus Therapeutics to Present Phase 1b Data on RBT-1 at Acute Kidney Injury & Continuous Renal Replacement Therapy 2021 Conference

DALLAS, Texas, Feb. 25, 2021 (GLOBE NEWSWIRE) — Rénibus Therapeutics, Inc., a clinical-stage biotech company focusing on the prevention, treatment, and diagnostic testing of kidney disease, announced today that it will present Phase 1b clinical trial data on RBT-1, its investigational treatment for the prevention of acute kidney injury (AKI), at the Acute Kidney Injury & Continuous Renal Replacement Therapy (AKI & CRRT) 2021 Conference, taking place virtually from February 28-March 5, 2021. 

The presentation will highlight safety data and biomarker responses in healthy volunteers and patients with chronic kidney disease (CKD). An ePoster will be available for viewing throughout the virtual conference, and the oral presentation will be provided by Richard Zager, MD, professor of medicine at the University of Washington, Seattle, on March 1, 2021 at 10:15 AM PST.

Rénibus Therapeutics presentation during AKI & CRRT          

Abstract Title  Presentation Details 
Biomarker and Safety Results from a Phase 1b Dose-Escalating Study of RBT-1 in Healthy Volunteers and Subjects with CKD Stage 3/4 ePoster: Available during poster sessions
Oral Presentation: Session 4 Clinical Research 2
March 1, 2021
10:15-11:15 AM PST

About Rénibus Therapeutics, Inc.

Founded in 2015, Rénibus Therapeutics is a clinical-stage biotech company dedicated to transforming the cardio-renal disease treatment paradigm by focusing on the prevention, treatment, and diagnostic testing of kidney disease. The company’s portfolio includes RBT-1 for prevention of acute kidney injury, RBT-2 for treatment of chronic kidney disease, RBT-3 for treatment of iron deficiency anemia and platinum-based kidney toxicity, RBT-6 for pharmacologic stress testing in kidney diseases, and RBT-9 for treatment of COVID-19 and other viral diseases.

Disclaimer

This article contains information regarding our future discovery, development efforts, business strategy, and market opportunities. This information constitutes a forward-looking statement. There are a number of risks and uncertainties that could cause our actual results to differ materially from those indicated by such forward-looking statements. These risks and uncertainties include those inherent in pharmaceutical research, such as adverse results in our drug discovery and clinical development processes, decisions made by the FDA and other regulatory authorities, market conditions, our ability to obtain, maintain and enforce proprietary rights and our ability to obtain any necessary financing to conduct our planned activities.

For more information, please visit the Company’s website at www.renibus.com.

Media contact: renibus@edelman.com

Staff

Recent Posts

Quibim Announces New Board of Directors To Promote Growth And Strategic Expansion

NEW YORK & VALENCIA, Spain & CAMBRIDGE, England--(BUSINESS WIRE)--#AIinHealthcare--Quibim, the global pioneer in imaging biomarkers…

1 hour ago

Waystar to Announce First Quarter 2025 Financial Results on April 30, 2025

LEHI, Utah and LOUISVILLE, Ky., April 7, 2025 /PRNewswire/ -- Waystar Holding Corp. (Nasdaq: WAY),…

4 hours ago

GREATER MIAMI JEWISH FEDERATION RELEASES JEWISH MIAMI: A 2024 COMMUNITY STUDY

DEMOGRAPHIC FINDINGS SHOW CONTINUED GROWTH, TREMENDOUS DIVERSITY AND DEEP CONNECTIONS TO ISRAEL AND JEWISH LIFE…

4 hours ago

Shapiro+Raj Expands Team with Strategic Hires to Accelerate Life Sciences Growth

CHICAGO, April 7, 2025 /PRNewswire/ -- Shapiro+Raj, the #1 Strategic and #12 Most Innovative Insights…

4 hours ago

CAS and Cleveland Clinic collaborate to accelerate research through advanced AI and quantum computing

COLUMBUS, Ohio, April 7, 2025 /PRNewswire/ -- CAS, a division of the American Chemical Society…

4 hours ago

Incuvio Health Launches to Help Payers and Providers Win in Value-Based Care

LOS ANGELES, April 7, 2025 /PRNewswire/ -- After years of navigating the complexities of payer systems,…

4 hours ago